Search

Additional file 2.

Additional file 4: Supplementary Table S3. Factors associated with patients’ overall survival.

Additional file 3: Supplementary Table S2. Perioperative characteristics in patients classified according to the cumulative duration of MAP

Additional file 5: Supplementary Table S4. Clinicopathologic characteristics in patients classified according to the median performance error.

Additional file 1 Figure S1. Protein-protein interaction analysis by PLA. Control of OVCA and CECA cell and description of Duo link PLA count method. (A) A2780s (ovarian cancer cells- OVCA), (B) C13 (cervical cancer cells – CECA), and (C) human ovarian tumour section without treatment of PLA reagents (contro. Blue represents DAPI (nucleus marker) and green represents TOM20 (mitochondria marker). (D) OV2008 cells treated without (CTL) or with CDDP were subjected to PLA assay. Using Duolink image tool, white dots (PLA signal) were counted either in mitochondria (green) or nucleus (Blue). Cell number was automatically assigned as shown by Duolink image tool. (E) PLA signal in each cell were counted, summed and averaged by number of cells as shown in table. Figure S2. CDDP increased Phb1 content and apoptosis in OV2008 cells, but not in C13* cells. (A) and (B) Comparison of Phb1 contents and apoptosis in OV2008 and C13* cultured with CDDP at different concentrations (A: 0–10 μM, 24 h) or for different duration (B: 0–24 h, 10 μM). Contents of Phb1 and GAPDH (loading control) were examined by Western blotting. Apoptosis was examined by Hoechst assay. Phb1 contents in OV2008 cells but not in C13* cells were significantly increased in the presence of CDDP in a concentration- (A; **p

Additional file 6: Supplementary Table S5. Clinicopathologic characteristics in patients classified according to wobble.

Additional file 2: Supplementary Table S1. Clinicopathologic characteristics in patients classified according to the cumulative duration of MAP

Additional file 1: Supplementary Table 1. Brief review of clinical courses of all patients. Abbreviations: NAC, Neoadjuvant chemotherapy; IDS, Interval debulking surgery; 95% CI, 95% confidence interval; OS, overall survival. Abbreviations: NGR, no gross residual; RT, residual tumor; 95% CI, 95% confidence interval; OS, overall survival.

Additional file 7.

Additional file 2.

Additional file 6.

Additional file 3.

Additional file 1.

Additional file 4.

Additional file 2: Table S1. Treatment administration in study population.